Sep 28, 2022
SAB’s fully-human polyclonal antibody platform maintains its efficacy against multiple variants of several highly mutating viruses SIOUX FALLS, S.D., Sept. 28, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy
Aug 10, 2022
Expects cash is sufficient to fund operations for the forward twelve months SIOUX FALLS, S.D., Aug. 10, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted,
Aug 04, 2022
SIOUX FALLS, S.D., Aug. 04, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), a clinical-stage biopharmaceutical company with a first of its kind immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors,